CT-868's effects on glucose homeostasis in Type 1 Diabetes to be evaluated in new clinical study

Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency. While exogenous insulin therapy is life-sustaining, achieving optimal glycemic control without increasing hypoglycemia risk remains a significant challenge. Many individuals with T1DM struggle with glycemic variability, requiring constant monitoring and dose adjustments. There is a critical unmet need for adjunctive therapies that can improve glucose homeostasis, reduce insulin requirements, and mitigate long-term complications beyond what insulin alone can provide. Exploring novel compounds like CT-868 for their potential to stabilize blood glucose in this population is therefore a key research area.